

REMARKS/ARGUMENTS

In the Restriction action issued 26 July 2004, a restriction requirement was raised between groups 1-13.

In response, Applicants herein elect claim Group 1, drawn to a method of inhibiting atrophy in skeletal muscles comprising treatment of cells with an inhibitor of Ras, including claims 1-2, 6, 34-35, and 39.

It was not clear to the undersigned if a species election was required if a claim group was selected which did not include one of claims 15, 18, 27, 28, 30, 33, or 41. Claim Group 1 does not list a series of species to be treated. However, in order to clarify the subject being treated, claims 1 and 34 are amended to recite "mammalian skeletal muscle cells". Support for the amendment is found in the specification at page 5, lines 8-10. No new matter is added by this amendment.


Conclusion

It is believed that this document is now fully responsive to the Restriction requirement raised in the Restriction action dated 26 July 2004. In light of the above amendments and remarks, it is believed that the claims are now in condition for allowance, and such action is respectfully urged.

Fees

Although it is believed that no fees are due, in the event the Patent Office determines that fees are due, the Commissioner is hereby authorized to charge Deposit Account Number 18-050 in the amount of any fees deemed to be due.

Respectfully submitted


Valeta Gregg, Ph.D., Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400